IDegLira Improves Cardiovascular Risk Markers in Patients with Type 2 Diabetes Uncontrolled on Basal Insulin: Analyses of DUAL II and DUAL V

被引：0
|
作者：
Vilsboll, Tina
Blevins, Thomas C.
Bode, Bruce
Leiter, Lawrence A.
Poulter, Neil
Thurman, Jerry
Agner, Bue F. Ross
Lehmann, Lucine
Jaeckel, Elmar
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
983-P
引用
收藏
页码：A255 / A255
页数：1
相关论文
共 50 条
  • [41] Efficacy of IDegLira vs. Basal-Bolus Therapy in Subjects with Type 2 Diabetes in DUAL VII by Baseline Characteristics
    Billings, Liana K.
    Klonoff, David C.
    Tentolouris, Nikolaos
    Gron, Randi
    Halladin, Natalie
    Jodar, Esteban
    [J]. DIABETES, 2018, 67
  • [42] LONG-TERM COST-EFFECTIVENESS OF IGLARLIXI VERSUS IDEGLIRA IN PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES TREATED WITH BASAL INSULIN OR ORAL ANTIDIABETIC DRUG IN CHINA
    Mo, X.
    Ai, Y.
    Tan, J.
    Wang, L. J.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S77 - S77
  • [43] The Dual GIP/GLP-1 Receptor Agonist Tirzepatide Improves Cardiovascular Risk Protein Biomarkers in Patients With Type 2 Diabetes
    Wilson, Jonathan M.
    Lin, Yanzhu
    Considine, Gary
    Cox, Amy L.
    Bowsman, Lenden M.
    Robins, Deborah A.
    Riesmeyer, Jeffrey S.
    Haupt, Axel
    Duffin, Kevin
    Ruotolo, Giacomo
    [J]. CIRCULATION, 2020, 142
  • [44] Safety and efficacy of IDegLira titrated once weekly vs twice weekly in patients with Type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI study
    Russell-Jones, D.
    Harris, S.
    Kocsis, G.
    Prager, R.
    Ridge, T.
    Chandarana, K.
    Halladin, N.
    Jabbour, S.
    [J]. DIABETIC MEDICINE, 2017, 34 : 160 - 160
  • [45] Euglycemia improves hyperglycemia-induced insulin resistance in patients with uncontrolled type 2 diabetes
    Pouwels, M
    Tack, C
    Hermus, A
    Lutterman, J
    [J]. DIABETOLOGIA, 2001, 44 : A190 - A190
  • [46] Effects of IDegLira (Insulin Degludec/Liraglutide) in Patients with Poorly Controlled Type 2 Diabetes (T2D) with A1C >9%-Analyses from the DUAL Program
    Sugimoto, Danny
    Frias, Juan P.
    Gouet, Didier
    Takacs, Robert
    Jia, Ting
    Orsy, Petra
    Bain, Stephen C.
    [J]. DIABETES, 2018, 67
  • [47] Insulin Degludec/Liraglutide (IDegLira) Improves Patient-Reported Impacts in Subjects with Type 2 Diabetes (T2D) Inadequately Controlled on Insulin Glargine (IG) plus Metformin (Met): DUAL V Study
    Brod, Meryl
    Manghi, Federico C. Perez
    Garcia-Hernandez, Pedro A.
    Norwood, Paul
    Jarlov, Henrik
    Kongso, Jens Harald
    Lingvay, Ildiko
    [J]. DIABETES, 2015, 64 : A644 - A644
  • [48] Tirzepatide, a dual GIP and GLP-1 receptor agonist, improves markers of beta cell function and insulin sensitivity in type 2 diabetes patients
    Thomas, M. K.
    Nikooienejad, A.
    Bray, R.
    Cui, X.
    Wilson, J.
    Duffin, K.
    Milicevic, Z.
    Haupt, A.
    Robins, D. A.
    [J]. DIABETOLOGIA, 2019, 62 : S354 - S354
  • [49] DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin
    Pei, Yu
    Agner, Bue R.
    Luo, Bin
    Dong, Xiaolin
    Li, Dongmei
    Liu, Jun
    Liu, Lei
    Liu, Ming
    Lu, Yibing
    Nishida, Tomoyuki
    Xu, Xiangjin
    Mu, Yiming
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (12): : 2687 - 2696
  • [50] Dual I China: improved glycaemic control with IDegLira versus its mono-components in Chinese patients with type 2 diabetes uncontrolled on oral antidiabetic drugs
    Wang, W.
    Agner, B.
    Luo, B.
    Liu, L.
    Liu, M.
    Peng, Y.
    Qu, S.
    Stachlewska, K. A.
    Wang, G.
    Zhang, Q.
    Ning, G.
    [J]. DIABETOLOGIA, 2020, 63 (SUPPL 1) : S332 - S333
12345